Abstract:Background Interleukin‐19 is an immunosuppressive cytokine produced by immune and nonimmune cells, but its role in abdominal aortic aneurysm (AAA) pathogenesis is not known. This study aimed to investigate interleukin‐19 expression in, and influences on, the formation and progression of experimental AAAs. Methods and Results Human specimens were obtained at aneurysm repair surgery or from transplant donors. Experimental AAAs were created in 10‐ to 12‐week‐old male mice via intra‐aortic elastase infusion. Influence and potential mechanisms of interleukin‐19 treatment on AAAs were assessed via ultrasonography, histopathology, flow cytometry, and gene expression profiling. Immunohistochemistry revealed augmented interleukin‐19 expression in both human and experimental AAAs. In mice, interleukin‐19 treatment before AAA initiation via elastase infusion suppressed aneurysm formation and progression, with attenuation of medial elastin degradation, smooth‐muscle depletion, leukocyte infiltration, neoangiogenesis, and matrix metalloproteinase 2 and 9 expression. Initiation of interleukin‐19 treatment after AAA creation limited further aneurysmal degeneration. In additional experiments, interleukin‐19 treatment inhibited murine macrophage recruitment following intraperitoneal thioglycolate injection. In classically or alternatively activated macrophages in vitro, interleukin‐19 downregulated mRNA expression of inducible nitric oxide synthase, chemokine C‐C motif ligand 2, and metalloproteinases 2 and 9 without apparent effect on cytokine‐expressing helper or cytotoxic T‐cell differentiation, nor regulatory T cellularity, in the aneurysmal aorta or spleen of interleukin‐19–treated mice. Interleukin‐19 also suppressed AAAs created via angiotensin II infusion in hyperlipidemic mice. Conclusions Based on human evidence and experimental modeling observations, interleukin‐19 may influence the development and progression of AAAs. Nonstandard Abbreviations and Acronyms AAA abdominal aortic aneurysm BMDM bone marrow–derived macrophage CCL chemokine (C‐C motif) ligand Foxp3 Forkhead Box P3 MMP matrix metalloproteinase PPE porcine pancreatic elastase rIL recombinant interleukin SMC smooth‐muscle cell TGF transforming growth factor Treg regulatory T cell Clinical Perspective What Is New? Recombinant cytokine interleukin‐19 suppressed the formation and progression of experimental abdominal aortic aneurysms in 2 distinct and complementary mouse abdominal aortic aneurysm modeling systems. Abdominal aortic aneurysm suppression by interleukin‐19 was associated with attenuation of medial elastin and smooth‐muscle destruction, mural leukocyte infiltration and neoangiogenesis, matrix metalloproteinases, and chemokine C‐C motif ligand 2. What Are the Clinical Implications? Medical interventions based on recombinant interleukin‐19 or its derivative strategies may hold the translational relevance for clinical abdominal aortic aneurysm disease management. Abdominal aortic aneurysm (AAA) is a common, age‐related degenerative disease of the infrarenal aortic segment. Characteristic histopathologic features of advanced AAA disease include medial elastin and vascular smooth‐muscle cell (SMC) depletion, transmural inflammatory cell accumulation, and neoangiogenesis. Multiple lines of evidence suggest that inflammation is central to the initiation and progression of AAAs, 1 including a recent prospective study showing the positive association of aortic uptake of ultrasmall superparamagnetic iron oxide particles with AAA enlargement, the risk for surgical aneurysm repair, and aneurysm‐specific mortality. 2 Cytokines are biologically active small peptides, recognized by their cognate receptors on targeting cells, and involved -Abstract Truncated-

Recombinant Interleukin-19 Suppresses the Formation and Progression of Experimental Abdominal Aortic Aneurysms.

Involvement of Macrophage-Derived Exosomes in Abdominal Aortic Aneurysms Development.

IL (Interleukin)-33 Suppresses Abdominal Aortic Aneurysm by Enhancing Regulatory T-Cell Expansion and Activity

Interleukin‐38 suppresses abdominal aortic aneurysm formation in mice by regulating macrophages in an IL1RL2‐p38 pathway‐dependent manner

Systemic Upregulation of IL-10 (Interleukin-10) Using a Nonimmunogenic Vector Reduces Growth and Rate of Dissecting Abdominal Aortic Aneurysm

Interleukin-22 Deficiency Reduces Angiotensin II-Induced Aortic Dissection and Abdominal Aortic Aneurysm in ApoE-/- Mice

Abstract 468: HIF-1α Mediates Initiation and Progression of Experimental Abdominal Aortic Aneurysms

The role and transformative potential of IL-19 in atherosclerosis

Inhibition of Interleukin-1β Decreases Aneurysm Formation and Progression in a Novel Model of Thoracic Aortic Aneurysms

Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas

C-reactive protein deficiency ameliorates experimental abdominal aortic aneurysms

Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment

RelB Represses Mir-193A-5p Expression to Promote the Phenotypic Transformation of Vascular Smooth Muscle Cells in Aortic Aneurysm

Group 2 Innate Lymphoid Cells Protect Mice from Abdominal Aortic Aneurysm Formation via IL5 and Eosinophils

Inhibition of miR-188-5p Suppresses Progression of Experimental Abdominal Aortic Aneurysms

Abstract 713: Angiotensin 1-7 Suppresses Experimental Abdominal Aortic Aneurysms

Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm

Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model

PC220 Angiotensin 1-7 Suppresses Experimental Abdominal Aortic Aneurysms

IL-5 overexpression attenuates aortic dissection by reducing inflammation and smooth muscle cell apoptosis

Type I Interferon Receptor Subunit 1 Deletion Attenuates Experimental Abdominal Aortic Aneurysm Formation